What's Driving The Uptick In Korea-China Biotech Deals
Bilateral ties between South Korea and China may have slumped to a new low, but that doesn’t seem to have deterred deals between firms in the two nations in the biotech space. Scrip takes a closer look at the deal-making flow and whether it is sustainable.
You may also be interested in...
Scrip takes a look at how the South Korean pharma/biotech industry's cross-border deals over the past few years compare with global trends, finding that oncology and diabetes have been the dominant therapeutic areas for the out-licensing of assets, but recent activity and value have declined from a peak in 2015.
The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.
Amid ongoing interest in accessing innovative assets, including those from South Korea, big pharma participants at a recent symposium in Seoul shared the ins and outs of the complex partnering process.